Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apellis Pharmaceuticals, Inc. (APLS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer listed on the Nasdaq Global Select Market, Apellis uses filings such as Forms 10-K, 10-Q, 8-K, and others to report on its business, financial condition, risk factors, and material events related to its complement-based therapies SYFOVRE and EMPAVELI/Aspaveli.
In these filings, investors can review detailed information on revenue from SYFOVRE and EMPAVELI, research and development spending for ophthalmology and rare disease programs, and the status of key clinical trials such as GALE and VALIANT. Risk factor and management discussion sections typically describe the scientific and regulatory considerations associated with targeting C3 in geographic atrophy, C3 glomerulopathy, primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria.
Current reports on Form 8-K, such as the Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi), document material definitive agreements that affect Apellis’ economics, including ex-U.S. royalty structures for Aspaveli and related financing consents. These filings help clarify how collaborations and capital arrangements support the company’s commercialization and pipeline strategy.
On Stock Titan, Apellis filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly understand topics like royalty arrangements, cash runway, product revenue trends, and major clinical or regulatory milestones. Users can also review Forms 4 and other insider transaction reports to monitor trading activity by Apellis directors and executives, alongside proxy and governance disclosures that describe compensation and board oversight. This page is a central resource for analyzing the regulatory record behind APLS stock.
Apellis Pharmaceuticals, Inc. insider transaction: Chief Technical Officer Nicholson Nur reported a sale of 2,203 shares of Apellis common stock on January 20, 2026, at a price of $19.7929 per share. According to the footnote, these shares were sold to cover tax withholding related to Restricted Stock Units that were released on January 16, 2026, rather than as an open-market discretionary sale. After this transaction, Nur beneficially owned 78,843 shares of Apellis common stock in direct ownership.
Apellis Pharmaceuticals Chief Financial Officer Timothy Eugene Sullivan reported a small sale of company stock primarily to cover taxes from equity compensation. On January 20, 2026, he sold 2,892 shares of common stock at an average price of $19.7929 per share, described as shares sold to cover tax withholding on restricted stock units that were released on January 16, 2026. After this transaction, he directly held 104,188 shares of Apellis common stock. In addition, 60,396 shares are held indirectly by The Timothy E Sullivan Irrevocable Trust of 2023, for which a separate trustee, Patrick O. Collins, acts, and over which Sullivan disclaims beneficial ownership except to the extent of his pecuniary interest.
Apellis Pharmaceuticals’ general counsel, David O. Watson, reported selling 2,475 shares of common stock on January 20, 2026 at $19.7929 per share. According to the filing, these shares were sold to cover tax withholding on restricted stock units that were released on January 16, 2026.
After this transaction, Watson beneficially owned 96,363 common shares directly. He also reported indirect holdings, including 10,000 shares in a custodial account for the sole benefit of his minor children, and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except for any pecuniary interest. The Watson Education Trust reported holding no shares following the reported transactions, with similar beneficial ownership disclaimers.
Apellis Pharmaceuticals insider plans to sell additional shares under Rule 144. A notice was filed to sell 2203 shares of common stock through Fidelity Brokerage Services LLC on or about 01/20/2026 on the NASDAQ market, with an aggregate market value of 43,603.76. The issuer had 126,525,218 common shares outstanding.
The 2203 shares to be sold were acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation. Over the prior three months, Nur Nicholson sold an additional 2618 common shares for gross proceeds of 58,086.09. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about Apellis Pharmaceuticals.
David O. Watson filed a Form 144 notice to sell 2,475 shares of common stock through Fidelity Brokerage Services LLC on or about January 20, 2026 on NASDAQ. The shares to be sold have an aggregate market value of $48,987.43, compared with 126,525,218 shares outstanding. These securities were acquired as restricted stock that vested on January 16, 2026 as compensation from the issuer. In the prior three months, Watson sold 5,000, 5,000, and 5,780 shares of common stock for gross proceeds of $100,300.00, $122,450.00, and $128,242.01, respectively.
Apellis Pharmaceuticals insider Cedric Francois has filed a Form 144 to potentially sell 8,182 shares of common stock. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $161,945.51 based on the figures in the notice. The stock was acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation.
The notice also reports that during the past three months, Francois sold 10,186 shares of common stock on 01/13/2026 for gross proceeds of $225,998.82. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
An APLS shareholder filed a notice of intent under Rule 144 to sell 1,334 common shares through Fidelity Brokerage Services LLC on 01/20/2026 on NASDAQ, with an aggregate market value of 26,403.73. These shares were acquired on 01/16/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 01/16/2026.
Over the prior three months, Mark J. Delong sold 1,780 common shares on 01/13/2026 for gross proceeds of 39,493.22. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Pascal Deschatelets has filed a Form 144 notice relating to common stock of APLS, indicating an intent to sell 909 shares through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 01/20/2026. These 909 shares were acquired on 01/16/2026 via restricted stock vesting from the issuer as compensation.
The notice also reports that during the past three months, Deschatelets sold 2,277 common shares for gross proceeds of 50520.25. The filing lists 126,525,218 shares of this class outstanding, providing context for the size of the planned and recent sales.
A shareholder has filed a notice of proposed sale of 1,882 common shares through Fidelity Brokerage Services LLC on 01/20/2026, with an aggregate market value of 37,250.24, to be sold on NASDAQ. The filing shows that 126,525,218 common shares were outstanding. The shares to be sold were acquired on 01/16/2026 via restricted stock vesting from the issuer as compensation.
During the prior three months, Caroline R. Baumal sold 3,020 common shares on 01/05/2026 for gross proceeds of 77,096.67. The person signing the notice represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
A holder of Apellis Pharmaceuticals (APLS) common stock has filed a notice under Rule 144 to sell restricted shares. The filing covers the planned sale of 2,892 common shares through Fidelity Brokerage Services on NASDAQ around 01/20/2026, with an indicated aggregate market value of $57,241.07. These shares were acquired from the issuer as restricted stock vesting on 01/16/2026 as compensation.
The notice also lists prior sales of the issuer’s common stock during the past three months by the same seller: 10,000 shares on 10/21/2025 for gross proceeds of $280,300.00, and 3,856 shares on 01/13/2026 for gross proceeds of $85,553.84. The filing notes that there were 126,525,218 common shares outstanding at the time indicated.